A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
Primary Purpose
Tinea Pedis
Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Oxiconazole Nitrate Cream 1%
Oxiconazole Nitrate Cream 1% (Oxistat®)
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Tinea Pedis focused on measuring Tinea Pedis
Eligibility Criteria
Inclusion Criteria:
- Male or non-pregnant, non-lactating female, 12 years of age or older.
- Signed informed consent form, which meets all criteria of current FDA regulations
- If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study {e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives)and (must have used the same product for at least 30 days prior to the study start and use the same product throughout the duration of the study), transdermal or implanted hormonal contraceptives}
- A confirmed clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot. (the non-interdigital lesions should not be hyperkeratotic i.e., characteristic of moccasin).
- The presence of tinea pedis infection, confirm by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.
Exclusion Criteria:
- Females who are pregnant, or lactating or likely to become pregnant during the study.
- Any known hypersensitivity to oxiconazole nitrate or other antifungal agents.
- Patients with a past history of tinea pedis infections with a lack of response to antifungal therapy (i.e. recurrent tinea pedis, more than 3 infections in the past 12 months, which were unresponsive to previous antifungal therapy).
- Participation in a research study in the past 30 days prior to screening/randomization.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Placebo Comparator
Arm Label
Oxiconazole Nitrate Cream 1%
Oxiconazole Nitrate Cream 1% (Oxistat®)
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Therapeutic Cure
Clinical & Mycological Cure at 6 weeks
Secondary Outcome Measures
Clinical Cure
Proportion of patients considered a clinical cure at 6 weeks
Mycological Cure
Proportion of patients with both KOH & culture negative at 6 weeks
Full Information
NCT ID
NCT01519752
First Posted
January 19, 2012
Last Updated
January 19, 2014
Sponsor
Taro Pharmaceuticals USA
1. Study Identification
Unique Protocol Identification Number
NCT01519752
Brief Title
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
Official Title
A Randomized, Double-Blind, Placebo Controlled, Parallel Design, Multiple-Site, Study Comparing Oxiconazole Nitrate Cream 1% (Taro Pharmaceuticals,Inc) to Oxistat® (Oxiconazole Nitrate Cream) Cream 1% (PharmaDerma) in the Treatment of Tinea Pedis
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
August 2012 (Actual)
Study Completion Date
November 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Taro Pharmaceuticals USA
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to demonstrate that Oxiconazole nitrate 1% topical cream is effective for the treatment of patients with moderate to severe Tinea pedis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tinea Pedis
Keywords
Tinea Pedis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
661 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Oxiconazole Nitrate Cream 1%
Arm Type
Experimental
Arm Title
Oxiconazole Nitrate Cream 1% (Oxistat®)
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Oxiconazole Nitrate Cream 1%
Intervention Description
Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
Intervention Type
Drug
Intervention Name(s)
Oxiconazole Nitrate Cream 1% (Oxistat®)
Intervention Description
Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo applied to affected area once a day for 28 days
Primary Outcome Measure Information:
Title
Therapeutic Cure
Description
Clinical & Mycological Cure at 6 weeks
Time Frame
Day 42
Secondary Outcome Measure Information:
Title
Clinical Cure
Description
Proportion of patients considered a clinical cure at 6 weeks
Time Frame
Day 42
Title
Mycological Cure
Description
Proportion of patients with both KOH & culture negative at 6 weeks
Time Frame
Day 42
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or non-pregnant, non-lactating female, 12 years of age or older.
Signed informed consent form, which meets all criteria of current FDA regulations
If female and of child bearing potential, prepare to abstain from sexual intercourse or use a reliable method of contraception during the study {e.g., condom, IUD, oral, transdermal, injected or implanted hormonal contraceptives)and (must have used the same product for at least 30 days prior to the study start and use the same product throughout the duration of the study), transdermal or implanted hormonal contraceptives}
A confirmed clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or predominantly interdigital, but may extend to other areas of the foot. (the non-interdigital lesions should not be hyperkeratotic i.e., characteristic of moccasin).
The presence of tinea pedis infection, confirm by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.
Exclusion Criteria:
Females who are pregnant, or lactating or likely to become pregnant during the study.
Any known hypersensitivity to oxiconazole nitrate or other antifungal agents.
Patients with a past history of tinea pedis infections with a lack of response to antifungal therapy (i.e. recurrent tinea pedis, more than 3 infections in the past 12 months, which were unresponsive to previous antifungal therapy).
Participation in a research study in the past 30 days prior to screening/randomization.
12. IPD Sharing Statement
Learn more about this trial
A Therapeutic Equivalence Study of Two Oxiconazole Nitrate Topical Cream Treatments for Patients With Tinea Pedis
We'll reach out to this number within 24 hrs